Cullinan Therapeutics Appoints New CFO
Cullinan Therapeutics, a biopharmaceutical firm known for its work on specific therapies, has named Mary Kay Fenton as its new Chief Financial Officer (CFO)
Mary Kay Fenton has over 30 years of financial and operational experience in the biotech business, having held key positions at Talaris Therapeutics and Semma Therapeutics prior to their acquisition by Vertex. She also served as CFO for Achillion Pharmaceuticals before it was acquired by AstraZeneca.